← Back to Search

Angiotensin Receptor Neprilysin Inhibitor

one arm for Heart Failure

N/A
Waitlist Available
Led By Gordon W Moe, MD, MSc
Research Sponsored by Unity Health Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 weeks, 4 weeks, 6 months, and 12 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

The purpose of this study is to compare the changes in B-type Natriuretic Peptide (BNP) and amino-terminal fragment of proBNP (NT-proBNP) in outpatients managed in the heart failure (HF) clinic initiated on the Angiotensin Receptor Neprilysin Inhibitor (Entresto) and directly compare the prognostic values of BNP and NT-proBNP in patients admitted with acute decompensated HF.

Eligible Conditions
  • Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 weeks, 4 weeks, 6 months, and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 weeks, 4 weeks, 6 months, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
In Patient Protocol
Out Patient Protocol

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: one armExperimental Treatment1 Intervention
One arm study patients where NT-proBNP and BNP tests will be monitored.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sacubitril
FDA approved

Find a Location

Who is running the clinical trial?

Alere, Inc.Industry Sponsor
3 Previous Clinical Trials
1,189 Total Patients Enrolled
1 Trials studying Heart Failure
930 Patients Enrolled for Heart Failure
Unity Health TorontoLead Sponsor
556 Previous Clinical Trials
454,106 Total Patients Enrolled
12 Trials studying Heart Failure
7,183 Patients Enrolled for Heart Failure
Gordon W Moe, MD, MScPrincipal InvestigatorUnity Health Toronto
~32 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top